US44975P1030
© PR Newswire
11.12.2025
IMAB
LISTED
NASDAQ
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
News Preview
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistanceThe study achieved its objective, as the new Q6W extended dosing interva...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
IMAB
LISTED
NASDAQ
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
News Preview
ROCKVILLE, Md., Dec. 10, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced the presentation of new data from the expanded 3mg/kg every 6 week (Q6W) Phase 1 dosing study for ragistomig, a bispeci...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
IMAB
LISTED
NASDAQ
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
News Preview
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistanceThe Phase 1 ragistomig study achieved its objective, as the new Q6W extended dosing interval produced strong anti-tumor efficacy in PD-L1-non-respo...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
04.12.2025
IMAB
LISTED
NASDAQ
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
News Preview
ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that new data from the expanded Phase 1 dosing study for ragistomig, a 4-1BB X PD-L1 bispecific antibody, will be prese...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
21.11.2025
IMAB
LISTED
NASDAQ
NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
News Preview
ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that its subsidiary Visara, Inc. (Visara) has appointed Cadmus C. Rich, MD, MBA, as its Chief Medical Officer (CMO), an...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
IMAB
LISTED
NASDAQ
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
News Preview
ROCKVILLE, Md., Oct. 29, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that its subsidiary Visara, Inc. (Visara) has assigned it exclusive license agreement to Everest Medicines (HKEX: 1952...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
IMAB
LISTED
NASDAQ
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
News Preview
New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide
Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
IMAB
LISTED
NASDAQ
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
News Preview
ROCKVILLE, Md., Oct. 29, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NovaBridge or the Company) today announced that it has changed its corporate name from I-Mab to NovaBridge Biosciences. The change was overwhelmingly approved by shareholders at the Company’s Extraordinary General Meeting held on October 24, 2025, and by the Company’s Board...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.10.2025
IMAB
LISTED
NASDAQ
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
News Preview
ROCKVILLE, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), is a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide, today announced that updated data from the Phase 1 study (NCT04900818) of givastomig as a monotherapy in heavily pre-treated pati...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
IMAB
LISTED
NASDAQ
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
News Preview
New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwide
Intention to pursue a Hong Kong initial public offering (IPO) to expand access...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2025
IMAB
LISTED
NASDAQ
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
News Preview
ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide, announced its new business model, focused on its global capabilities built to accelerate access to innovative medicines and to enabl...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
IMAB
LISTED
NASDAQ
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
News Preview
ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract related to updated data from the Phase 1 study of givastomig as a monotherapy in heavily pre-treated...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
08.09.2025
IMAB
LISTED
NASDAQ
I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments
News Preview
ROCKVILLE, Md., Sept. 08, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced accelerated investment in its lead program, givastomig, an investigational Claudin 18.2 (CLDN18.2)-direct...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
IMAB
LISTED
NASDAQ
I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update
News Preview
ROCKVILLE, Md., Aug. 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the three and six months ended June 30, 2025, and highlighted recent pipeline progres...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.08.2025
IMAB
LISTED
NASDAQ
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares
News Preview
ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the pricing of an underwritten offering in the United States of 33,333,334 American Depositary Shares (ADSs) represe...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2025
IMAB
LISTED
NASDAQ
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
News Preview
ROCKVILLE, Md., July 17, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that it entered into a definitive agreement to acquire 100% ownership of Bridge Health Biotech Co., Ltd. (Bridge Hea...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.07.2025
IMAB
LISTED
NASDAQ
I-Mab to Present at the BTIG Virtual Biotechnology Conference
News Preview
ROCKVILLE, Md., July 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the BTIG Virtual Biotechnology Conference, being held on July 29-...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2025
IMAB
LISTED
NASDAQ
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
News Preview
Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
IMAB
LISTED
NASDAQ
I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research
News Preview
Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.06.2025
IMAB
LISTED
NASDAQ
I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement
News Preview
ROCKVILLE, Md., June 12, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that on June 11, 2025 it received notification from The Nasdaq Stock Market LLC (“Nasdaq”) notifying th...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.05.2025
IMAB
LISTED
NASDAQ
I-Mab to Present at Jefferies Global Healthcare Conference
News Preview
ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the Jefferies Global Healthcare Conference, being held June 3-5, 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2025
IMAB
LISTED
NASDAQ
I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update
News Preview
ROCKVILLE, Md., May 15, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the three months ended March 31, 2025, and highlighted recent pipeline progress and business...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.04.2025
IMAB
LISTED
NASDAQ
I-Mab Reports Full Year 2024 Financial Results and Provides Business Update
News Preview
ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the full year ended December 31, 2024, and highlighted recent pipeline progress and busines...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.03.2025
IMAB
LISTED
NASDAQ
I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
News Preview
ROCKVILLE, Md., March 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), announced today that on March 19, 2025 it received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid pric...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.03.2025
IMAB
LISTED
NASDAQ
I-Mab Announces Accelerated Givastomig Phase 1b Study Progress
News Preview
ROCKVILLE, Md., March 07, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that enrollment has been completed ahead of schedule in the first dose expansion cohort in the Phase 1b givastomi...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
IMAB
LISTED
NASDAQ
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
News Preview
Chairman of the Board, Wei Fu, informed the Company of his intent to purchase up to $2,000,000 of the Company's American Depository Shares (ADSs)
ROCKVILLE, Md., Jan. 8, 2025 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2025
IMAB
LISTED
NASDAQ
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
News Preview
Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritizationThe Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient do...
Themefolio
Profiler
Peergroup
© PR Newswire
21.11.2024
IMAB
LISTED
NASDAQ
I-Mab to Participate at the Piper Sandler Healthcare Conference
News Preview
The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024
ROCKVILLE, Md., Nov. 21, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB, the "Company"), a U.S.-based global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2024
IMAB
LISTED
NASDAQ
I-Mab Reports Third Quarter 2024 Results
News Preview
Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy dataOn track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents,...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
IMAB
LISTED
NASDAQ
I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
News Preview
ROCKVILLE, Md., Nov. 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu, PhD, MBA has been appointed as the Company's permanent Chief Executive Officer...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
IMAB
LISTED
NASDAQ
I-Mab to Release Q3 2024 Financial Results on November 14, 2024
News Preview
ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday,...
Themefolio
Profiler
Peergroup
© PR Newswire
28.10.2024
IMAB
LISTED
NASDAQ
I-Mab to Participate at the Truist Securities BioPharma Symposium
News Preview
ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPha...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2024
IMAB
LISTED
NASDAQ
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
News Preview
Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levelsThe recommended Phase 2 dose for givastomig was determined to be 8-12 mg/kg; givastomig was well tole...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2024
IMAB
LISTED
NASDAQ
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
News Preview
- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials- Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients- Randomized Phase 2 study of uliledlimab in combination with pembrolizumab...
Themefolio
Profiler
Peergroup
© PR Newswire
28.08.2024
IMAB
LISTED
NASDAQ
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates
News Preview
Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 20...
Themefolio
Profiler
Peergroup
© PR Newswire
26.08.2024
IMAB
LISTED
NASDAQ
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
News Preview
ROCKVILLE, Md., Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference on Septemb...
Themefolio
Profiler
Peergroup
© PR Newswire
14.08.2024
IMAB
LISTED
NASDAQ
I-Mab to Release 1H 2024 Financial Results on August 28, 2024
News Preview
Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET
ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treat...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.05.2024
IMAB
LISTED
NASDAQ
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
News Preview
ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that Gerald Falchook, MD, and the team at I-Mab’s partner for ragis...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
